Metformin for the treatment of polycystic ovary syndrome
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To familiarize obstetrician-gynecologists with the use of metformin for the treatment of polycystic ovary syndrome (PCOS). DATA SOURCES: Using OVID, 94 English-language articles published after 1966 indexed with the key words "metformin" and "polycystic ovary syndrome" were identified. METHODS OF STUDY SELECTION: Studies were excluded if they did not have a control group, did not use the National Institutes of Health definition of PCOS, did not have a clinical outcome as an end point, and were not in the English language. Reviews were also excluded, leaving 21 articles for inclusion. TABULATION, INTEGRATION, AND RESULTS: Three clinical trials reported that for the treatment of anovulatory infertility caused by PCOS, metformin plus clomiphene is more effective than clomiphene alone in inducing ovulation. For the treatment of irregular menses caused by PCOS in women not attempting conception, metformin therapy may restore ovulatory menses in the majority of women. However, most women will require 4-6 months of metformin therapy before they achieve ovulatory menses. In obese women, metformin plus a low-calorie diet may be associated with more weight loss than a low-calorie diet alone. CONCLUSION: Polycystic ovary syndrome is a common gynecologic endocrine disorder. Obstetrician-gynecologists should be familiar with the indications and contraindications for the use of metformin in their practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368 · cited 1×
“31 However, the development of anemia is rare.(30) For women on chronic metformin, measurement of red blood cell concentration is recommended on an annual schedule.”
BackgroundPharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 1×
“Interestingly, metformin-induced weight loss appears to preferentially involve adipose tissue.(71)”
BackgroundKiddy, D. S., Hamilton‐Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M. J., & Franks, S. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02909.x · Cited by 921
Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865 · cited 1×
“Most studies demonstrate that insulin sensitizers, such as metformin, decrease serum testosterone, which should have a beneficial effect on hirsutism.(45,46) In a prospective cohort study, treatment of obese women with PCOS with metformin (1500 mg daily) for 4–6 months improved menstrual cyclicity in 69% of the patien…”
BackgroundNestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743
Pasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G. E., Filicori, M., & Morselli-Labate, A. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6738 · Cited by 635 · cited 1×
“In another trial, metformin (850 mg twice daily) plus a low-calorie diet (1200–1400 kcal daily) was demonstrated to be superior to a low-calorie diet alone in facilitating weight loss in both women with PCOS and obese women who did not have hirsutism and irregular menses.(65)”
MethodAccumulation of Metformin by Tissues of the Normal and Diabetic Mouse
Wilcock, C., & Bailey, C. J. (1994) · Xenobiotica · doi:10.3109/00498259409043220 · Cited by 418 · cited 1×
“cause build up of lactic acid in the bowel wall.(23) In laboratory animals taking metformin, no significant histologic changes in the bowel mucosa have been identified.”
Background
Cited by
Identifying Children at Risk for Polycystic Ovary Syndrome
Rosenfield, R. L. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2012 · Cited by 288
Marsh, K. A., Steinbeck, K. S., Atkinson, F. S., Petocz, P., & Brand-Miller, J. C. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29261 · Cited by 228
Glueck, C. J., Dharashivkar, S., Wang, P., Zhu, B., Gartside, P. S., Tracy, T., & Sieve, L. (2005) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2005.03.010 · Cited by 99
“Given their obesity [4,5–8,29–31,33,35,37,38] and hyperinsulinemia, it is not surprising that women with PCOS commonly have the coronary heart disease risk factors which, along with waist circumference >88 cm, make up the metabolic syndrome [18] (systolic blood pressure 130, diastolic blood pressure 85 mmHg, triglycer…”
Background
Metadata
- Authors
- Barbieri, R.
- Venue
- Obstetrics & Gynecology
- Published
- 2003-04
- Volume
- 101
- Issue
- 4
- Pages
- 785-793
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2063996773
- Cited by
- 84
- References
- 18
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin for the treatment of polycystic ovary syndrome. https://app.cochat.ai/papers/10.1016/s0029-7844(03)00045-0
- The paper
- Barbieri, R. (2003). Metformin for the treatment of polycystic ovary syndrome. Obstetrics & Gynecology. https://doi.org/10.1016/s0029-7844(03)00045-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.